Biogen CEO Chris Viehbacher at the Financial Times' US Pharma and Biotech Summit in May (Sarah Merians Photography for Endpoints News)

Hints of im­pa­tience grow with Bio­gen as it tries to find a bridge to growth

Bio­gen’s in­vestors are grow­ing rest­less.

Wednes­day’s third-quar­ter earn­ings call checked most of the box­es for a suc­cess­ful re­port. The com­pa­ny raised its full-year guid­ance, and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA